Related Experiment Videos
A highly restricted antigen for renal cell carcinoma defined by a monoclonal antibody
Abstract:
Monoclonal antibodies against renal cell carcinoma (RCC) antigens were generated by immunizing Balb/c mice with the human RCC cell line 7860. After cloning many RCC reactive monoclonal antibodies, one antibody (D5D), was of special interest. Specificity testing against 33 human tumor cell lines revealed D5D to have no specific reactivity with 17 specimens of normal adult or fetal kidney. Reactivity with 67 specimens of nonrenal tissue demonstrated no reactivity. The reactivity of D5D with 15 different RCC tissues has been variable, being present in 60% of cases. Preliminary data, however, suggest that the antigen may be reexpressed for some of the remaining 40% during in vitro propagation.
Insights
Researchers developed a novel monoclonal antibody (D5D) targeting renal cell carcinoma (RCC) antigens. This antibody shows promise, reacting with 60% of RCC tissues and exhibiting no reactivity with normal kidney or non-renal tissues.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Renal cell carcinoma (RCC) is a significant global health concern.
- Development of targeted therapies for RCC remains a critical area of research.
- Monoclonal antibodies offer a promising avenue for specific cancer targeting.
Purpose of the Study:
- To generate and characterize novel monoclonal antibodies against RCC-specific antigens.
- To evaluate the specificity and reactivity of a candidate antibody (D5D) against RCC and normal tissues.
- To assess the potential of D5D for targeted RCC therapy.
Main Methods:
- Immunization of Balb/c mice with the human RCC cell line 7860.
- Cloning and screening of RCC-reactive monoclonal antibodies.
- Extensive specificity testing using a panel of 33 human tumor cell lines, 17 normal kidney specimens, and 67 non-renal tissues.
- Assessment of D5D reactivity with 15 distinct RCC tissue specimens.
Main Results:
- One antibody, D5D, demonstrated significant promise.
- D5D showed no reactivity with normal adult or fetal kidney tissues.
- D5D exhibited no reactivity with 67 tested non-renal tissues.
- Reactivity of D5D with 15 RCC tissues was variable, present in 60% of cases.
- Preliminary data suggest potential re-expression of the antigen in vitro for non-reactive cases.
Conclusions:
- The D5D monoclonal antibody is a specific reagent for a subset of renal cell carcinoma (RCC) cases.
- D5D demonstrates excellent specificity, lacking reactivity with normal kidney and non-renal tissues.
- Further investigation into the antigen's re-expression could expand the therapeutic potential of D5D in RCC treatment.